Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
25 April 2024 - 10:00PM
Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical
stage biopharmaceutical company focused on developing novel
therapeutics to address unmet medical needs in liver and viral
diseases, wishes to express its condolences on the recent passing
of Stephen A. Harrison, MD., Col (Ret.), FAASLD, who served as a
trusted advisor and the Principal Investigator for the Company’s
ongoing Phase 2a HERALD study in metabolic dysfunction-associated
steatohepatitis (MASH) subjects.
“On behalf of the entire Aligos team, we are deeply saddened by
the news of Dr. Harrison’s passing,” said Lawrence Blatt, Ph.D.,
MBA, Chairman, President, and Chief Executive Officer at Aligos
Therapeutics. “Dr. Harrison’s immense contributions and passion for
the MASH space paved the way for the first drug approval in MASH
and his efforts in the field have led to numerous benefits for
patients suffering from this disease. He was a delight to work
with, learn from, and his expertise will be greatly missed. We send
our deepest condolences to Dr. Harrison’s family, friends, and
colleagues.”
Thanks to Dr. Harrison’s expertise in designing and implementing
HERALD, the study is continuing to enroll, dose subjects, and
remains on track for the anticipated topline data readout in Q4
2024.
About AligosAligos Therapeutics, Inc. is a
clinical stage biopharmaceutical company that was founded in 2018
with the mission to become a world leader in the treatment of liver
and viral diseases. Aligos’ strategy is to harness the deep
expertise and decades of drug development experience its team has
in liver and viral diseases to discover and develop potentially
best-in-class therapeutics for metabolic dysfunction-associated
steatohepatitis (MASH) and viruses with high unmet medical need
such as hepatitis B and coronaviruses.
Forward-Looking Statement This press release
contains forward-looking statements within the meaning of the U.S.
Private Securities Litigation Reform Act of 1995. Any statements in
this press release that are not historical facts may be considered
“forward-looking statements,” including without limitation,
statements, that the study, HERALD, is continuing to enroll, dose
subjects and remains on track for anticipated topline data readout
in Q4 2024. Forward-looking statements are typically, but not
always, identified by the use of words such as “may,” “will,”
“would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,”
“expect,” and other similar terminology indicating future results.
Such forward looking statements are subject to substantial risks
and uncertainties that could cause our development programs, future
results, performance, or achievements to differ materially from
those anticipated in the forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
inherent in the drug development process, including Aligos’
clinical-stage of development, the process of designing and
conducting clinical trials, the regulatory approval processes, the
timing of regulatory filings, the challenges associated with
manufacturing drug products, Aligos’ ability to successfully
establish, protect and defend its intellectual property, other
matters that could affect the sufficiency of Aligos’ capital
resources to fund operations, reliance on third parties for
manufacturing and development efforts, and the impact of global
events and other macroeconomic conditions on the Aligos’ business.
For a further description of the risks and uncertainties that could
cause actual results to differ from those anticipated in these
forward-looking statements, as well as risks relating to the
business of Aligos in general, see Aligos’ Quarterly Report on Form
10-K filed with the Securities and Exchange Commission on March 12,
2024 and its future periodic reports to be filed or submitted with
the Securities and Exchange Commission. Except as required by law,
Aligos undertakes no obligation to update any forward-looking
statements to reflect new information, events or circumstances, or
to reflect the occurrence of unanticipated events.
Contacts
CompanyJordyn TaraziVice President, Investor
Relations & Corporate Communications(650)
910-0427jtarazi@Aligos.com
MediaMichael Fitzhugh LifeSci Communications
mfitzhugh@lifescicomms.com
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From Apr 2024 to May 2024
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From May 2023 to May 2024